CVS Health CEO says private insurers will not cover GLP-1s for weight loss until prices drop

CVS Health CEO David Joyner stated private health plans will continue to largely exclude coverage of GLP-1 drugs like Wegovy and Zepbound for weight loss until manufacturers lower prices. His comments reflect the mounting financial strain these drugs place on employer-sponsored plans, with some analysts projecting annual costs exceeding $100 billion if coverage expands broadly. This stance signals a prolonged access battle for patients seeking anti-obesity medications outside Medicare's limited GLP-1 Bridge program. Practices should expect strict prior authorization criteria and high patient cost-sharing for these drugs on commercial plans for the foreseeable future, complicating treatment initiation and adherence discussions.